#London #United Kingdom #Implantica #RefluxStop #GORD

Implantica's Educational Meeting for RefluxStop™ Treatment

In January 2025, Implantica AG, a leading medtech company, marked a significant milestone by hosting the first educational event centered on the RefluxStop™ device. This innovative meeting took place at the prestigious NHS Chelsea Westminster Hospital in the UK, gathering top gastrointestinal experts eager to learn about advancements in the treatment of gastroesophageal reflux disease (GORD).

The RefluxStop™ device represents a pioneering approach to address acid reflux—a condition affecting over a billion people worldwide. The meeting facilitated in-depth discussions about the mechanism of action of RefluxStop™, which distinguishes itself by treating the root cause of acid reflux without altering the food passageway. Leading surgeons, Mr. Naim Gomez and Mr. James Brewer, have already commenced operations with this device, reporting successfully treated patients who have experienced remarkable improvements in their quality of life.

During the educational session, Mr. Gomez expressed his optimism regarding the RefluxStop™ procedure, stating, "The results we have observed thus far are compelling. Patients have demonstrated significant enhancements in daily living, which is truly rewarding for those who have long suffered from this debilitating condition."

The emphasis on education during this meeting underscores Implantica's dedication to ensuring that the GI community is well-informed about the latest advancements in reflux treatment. The gathering included a diverse group of eleven gastroenterologists who engaged in discussions about patient selection criteria, clinical data support, and anticipated procedural outcomes.

Mr. Brewer commented on the procedure's potential, highlighting that it could provide surgical options for patients previously deemed unsuitable candidates for conventional anti-reflux surgeries. He emphasized the groundbreaking nature of RefluxStop™, particularly noting its innovative mechanism that revitalizes the lower esophageal sphincter while maintaining its natural positioning.

Dr. Peter Forsell, Implantica's CEO and founder, expressed gratitude to the Chelsea Westminster team for their commitment to innovation and education in surgical treatments for GORD. His acknowledgment further solidifies the growing community of surgeons embracing the RefluxStop™ procedure, indicating a promising future for patients in need of effective treatments for GORD.

Dr. Forsell stated, "It's inspiring to see the NHS, one of Europe’s largest healthcare systems, implement RefluxStop™. It's a testament to the device's substantial benefits and the advancements in medical technology aimed at enhancing patients' lives."

The adoption of RefluxStop™ is part of a larger vision by Implantica to innovate healthcare technology and improve outcomes. Their other notable focus areas include developing eHealth technologies that monitor health parameters and remotely control treatments.

The RefluxStop™ device, having achieved CE-marking, is poised to alter the standard of care in anti-reflux surgical treatment significantly. With positive clinical trial results backing its efficacy, it promises to replace traditional methods, which often involve restrictive procedures that may cause adverse effects such as swallowing difficulties and pain.

As the medical community progresses toward implementing RefluxStop™, its potential to change the landscape of GORD treatment increases. Both patients and medical professionals alike anticipate witnessing its impact on managing gastroesophageal reflux disease in the years to come. Implantica's efforts not only reflect a significant advancement in medical technology but also present hopeful prospects for countless patients suffering from acid reflux.